Immunotherapy / PD-1 inhibitorInvestigationalInvestigational
Dostarlimab
How it works
Blocks the action of a protein called programmed death-1 (PD-1), which is involved in the regulation of the immune system. This allows the immune system to recognize and attack cancer cells.
Cancer types
Colorectal Cancer— All patients
Ovarian Cancer— PD-L1-positive
Efficacy
Clinical trials are ongoing to evaluate the efficacy of dostarlimab in patients with ovarian cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Treatment Combination Shows Modest Progression-Free Survival Benefit in Advanced Ovarian Cancer | Ovarian Cancer | phase-3 | The primary endpoint was investigator-assessed progression-free survival (PFS) as per RECIST v1.1, with a median of 20.6 months in arm 3 versus 19.2 months in arm 2. | Source → |
| New Treatment Combination Shows Modest Activity in Advanced Ovarian Cancer | Ovarian Cancer | phase-2 | The objective response rate was 17.1% (80% CI, 9.8 to 27.0), including one complete response (2.4%). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.